Latest Breaking News On - European summary - Page 1 : comparemela.com

Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)

Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United kingdomBecker hewesMastocytosis advEuropean hematology associationBlueprint medicines corporationEuropean academy of allergyPrnewswire blueprint medicines corporation nasdaqEuropean commissionPatient surveyExchange commissionDrug administrationPatient survey abstractMedicines corporationClinical immunologyHematology associationHybrid congress

UCB : presents final open-label extension F®▼(fenfluramine) data at International Child Neurology Congress (ICNC) Annual Meeting

UCB : presents final open-label extension F®▼(fenfluramine) data at International Child Neurology Congress (ICNC) Annual Meeting
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Cape townWestern capeSouth africaBruxelles capitaleLaurent schotsAntje witteNick francisInternational child neurology congressGlobal communicationsEuronext brusselsInternational child neurologyEpileptic encephalopathiesSafety informationChild pugh classEuropean summaryProduct characteristics

Genmab A/S : Interim Report for the First Quarter of 2024

Genmab Announces Financial Results for the First Quarter of 2024 May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended.

Genmab duobodyTivdak genmabAndrew carlsenInformationfor tivdakGenmab abbvieMarisol peronAbbvie incSociety of gynecologic oncologyExchange commissionPfizer incEuropean medicines agencyUs national comprehensive cancer networkCompany announcementMedarex incJanssen biotech incProfoundbio inc

BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer

BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomMark lanasaLuis pazLiza heapesKyle blankenshipEuropean medicines agencyEuropean society of medical oncologyBeigene ltdEuropean unionEuropean commissionHead of the medical oncology serviceDrug administrationExchange commissionChief medical officerSolid tumorsLuis paz ares

BeiGene, Ltd : BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer

BeiGene, Ltd : BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomDennis riedlKyle blankenshipLuis pazMark lanasaLiza heapesEuropean society of medical oncologyBeigene ltdEuropean unionDrug administrationEuropean medicines agencyEuropean commissionExchange commissionHead of the medical oncology serviceChief medical officerSolid tumors